The stock research analysts at Barclays lowered their price target for UiPath (NYSE: PATH), taking it from $15.00 down to $13.00. The announcement was made in a research note that was released on Tuesday. From the perspective of the price objective established by Barclays, there is room for the stock to move higher from where it is currently trading, which is 2.36%.
Additionally, other papers have devoted some space to discussing PATH at length. The price objective that Mizuho has placed on UiPath has increased from $14.00 to $15.00, as stated in a research report that was made available to the general public on Friday, December 2nd. The price objective that JPMorgan Chase & Co. has set for UiPath has been reduced from $18.00 to $16.00, as stated in a research report that was made public on Friday, December 2nd. The company also assigned a “neutral” rating to its trading stock. Canaccord Genuity Group rated the stock as a “hold” in a research report that was made public on Friday, September 30th, and decreased their price objective on UiPath from $15.00 to $14.00. The report was published on Canaccord Genuity Group’s website. The stock of the company was the subject of the study. In a research report published on November 16th, Credit Suisse Group lowered its “outperform” rating and price target on UiPath stock, which had previously been set at $30.00. The new price target is $27.50.
Last but not least, Evercore ISI stated in a research note made public on Friday, December 2nd, that they would be lowering their price target for UiPath shares to $17.00. This information was included in the report that was made public. Seven financial analysts have issued a buy recommendation for the stock, while nine others have advised investors to maintain their current shares. According to the information provided by Bloomberg, the current recommendation for UiPath is “Hold,” and the company’s share price is anticipated to range between $17.97 and $18.00 in the not-too-distant future.
When trading started on Tuesday, one share of UiPath stock was going for $12.70 per share. The company’s simple moving average over the past fifty days comes in at $12.34, and the simple moving average over the past two hundred days comes in at $15.03. The stock presently carries a price-to-earnings ratio of -18.95, a beta value of 0.38, and a market capitalization of $7.02 billion. UiPath reached a new all-time high of $42.78 in the last year, while it hit a new all-time low of $10.40 in that same period.
On December 1st, UiPath (NYSE: PATH) distributed its most recent quarterly earnings report. This report covered the company’s performance over the past three months. The healthcare provider reported earnings per share of $0.09, which was $0.09 higher than the consensus estimate for the quarter, which was $0.18. The company’s sales for the period in question came in at $262.74 million, significantly higher than the consensus expectation of $248.07 million, which had been calculated before the period in question. At the end of the fiscal year, UiPath’s return on equity was negative at 17.19%, and the company’s net margin was also negative at 34.99%. According to the forecasts provided by industry analysts, UiPath is anticipated to experience a loss of 0.55 cents per share during the current fiscal year.
On October 19th, Chief Administrative Officer Hitesh Ramani completed the sale of 2,100 shares of UiPath stock. Other news includes the following: The price received for each share was an average of $12.10, and the total amount received from the stock sale was $25,410.00. The chief accounting officer now has direct ownership of 395,717 shares in the company as a direct result of the transaction that took place earlier. These shares are currently trading at a price corresponding to a market value of approximately $4,788,175.70. On the website of the Securities and Exchange Commission, the disclosure document that included the information about the transaction can be accessed in its entirety at any time. Ashim Gupta, who serves as the company’s chief financial officer, sold a total of 10,000 shares of company stock on November 1st. The shares were sold for a volume of 124,800.00 dollars at an average price of $12.48 per share, which resulted in a total of 124,800.00 dollars. Following the completion of the transaction, the chief financial officer will have a total of 1,565,376 shares in the company. The value of these shares at present is $19,535,892.48. On the Securities and Exchange Commission’s (SEC) website, you can access the information submitted to the SEC regarding the transaction, which is currently available.
Additionally, on October 19th, Chief Administrative Officer Hitesh Ramani sold 2,100 shares of UiPath stock. The total amount received for the sale of the shares was $25,410.00, and the price paid for each share came to an average of 12.10 dollars. Because of the transaction, the chief accounting officer now owns 395,717 company shares with a combined value of $4,788,175.70. Disclosures that are related to the sale might be found in this section of the website. Over the most recent three months, employees with insider trading privileges on their accounts sold 34,700 company stock for a total of $442,269; the company’s insiders own the shares of stock in the company to the extent of 31.88%.
In recent times, institutional investors have been engaged in purchasing and selling shares in various companies. Raymond James Financial Services Advisors Inc. increased the proportion of its holdings that are comprised of UiPath by 3.8% over the first three months of 2018. After making an additional purchase of 1,506 shares during the most recent fiscal quarter, Raymond James Financial Services Advisors Inc. now owns 40,993 shares in the healthcare business. These shares have a value of $885,000, and the company’s holdings are worth $885,000. During the first three months of 2018, MetLife Investment Management LLC made a new holding investment with a total value of 184,000 dollars. BlackRock Inc.’s holdings in UiPath saw a 1.9% increase during the first three months of 2018 thanks to the investment firm’s purchases. BlackRock Inc. now has a total of 5,316,635 shares of the healthcare company’s stock following the acquisition of an additional 99,242 shares during the most recent period. The stock currently has a total value of $114,786,000 due to BlackRock Inc.’s ownership of these shares. During the first three months of 2018, Dimensional Fund Advisors LP made a fresh investment in UiPath for 534 thousand dollars. The Canada Pension Plan Investment Board expanded its holdings with a new investment during the first quarter, which consisted of 259,000 dollars worth of UiPath stock and was valued at that amount. Shares of the company are currently owned by various types of institutional investors, including hedge funds, to the extent of 56.40 percent.
Robotic process automation (RPA) solutions, such as those manufactured by UiPath Inc., are extensively utilized by many businesses in various countries, including the United States of America, Romania, and Japan. These solutions form an essential part of an end-to-end automation platform. The company assists other businesses in creating, running, engaging, measuring, and managing automation by making available to those businesses a set of software tools that are interconnected with one another.